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Abstract Previous studies by Papermaster and coworkers in-
troduced the use of rhodopsin^green £uorescent protein (rho^
GFP) fusion proteins in the construction of transgenic Xenopus
laevis with retinal rod photoreceptor cell-speci¢c transgene ex-
pression [Moritz et al., J. Biol. Chem. 276 (2001) 28242^
28251]. These pioneering studies have helped to develop the
Xenopus system not only for use in the investigation of rhodop-
sin biosynthesis and targeting, but for studies of the phototrans-
duction cascade as well. However, the rho^GFP fusion protein
used in the earlier work had only 50% of the speci¢c activity of
wild-type rhodopsin for activation of transducin and only 10%
of the activity of wild-type in rhodopsin kinase assays. While
not a problem for the biosynthesis studies, this does present a
problem for investigation of the phototransduction cascade. We
report here an improved rhodopsin/EGFP fusion protein in
which placement of the EGFP domain at the C-terminus of
rhodopsin results in wild-type activity for activation of trans-
ducin, wild-type ability to serve as a substrate for rhodopsin
kinase, and wild-type localization of the protein to the rod pho-
toreceptor cell outer segment in transgenic X. laevis.
9 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The South African clawed frog, Xenopus laevis, has been
used extensively in developmental biology as a model organ-
ism for more than half a century [2], but techniques for the
generation of transgenic Xenopus have been introduced by
Kroll and Amaya only relatively recently [3]. Subsequently,
Knox and colleagues characterized the Xenopus rhodopsin
gene [4] and used the promoter to generate transgenic X. laevis
in which transgene expression was speci¢c for retinal rod
photoreceptor cells [5]. Papermaster and colleagues then ex-
ploited this approach beautifully to elucidate mechanisms of
rhodopsin transport and tra⁄cking within the rod photore-
ceptor [1,6^8]. Because of the e¡orts of Knox and Papermas-
ter and others, X. laevis is rapidly becoming a model system of
choice for understanding the molecular biology of vertebrate
phototransduction.
To facilitate their studies of rhodopsin biosynthesis and
transport in the transgenic frog model, Moritz et al. [1] gen-
erated a rhodopsin^green £uorescent protein (rho^GFP) fu-
sion protein in which GFP was inserted in the C-terminus of
bovine rhodopsin following Thr335 (the insertion also resulted
in a duplication of amino acids Ser334 and Thr335 following
the GFP sequence). The rho^GFP fusion protein was of great
usefulness in identifying transgenic animals and in monitoring
biosynthesis and tra⁄cking patterns of rhodopsin. However,
the speci¢c activity of this protein under in vitro conditions
was only half that of wild-type rhodopsin in transducin assays
and only one-tenth that of wild-type in rhodopsin kinase
(RK) assays. While this is not a problem for investigations
of protein biosynthesis or gene regulation, it does present
some concern for studies of the phototransduction cascade.
Here we report a rhodopsin/enhanced GFP (rho/EGFP) fu-
sion protein with signi¢cantly improved folding characteristics
and in vitro activity for use in generating transgenic X. laevis.
2. Materials and methods
2.1. Materials
The design and chemical synthesis of the gene for rhodopsin used in
these studies has been published [9]. pEGFP-C2 and pEGFP-N1,
sources of the gene for EGFP, were from Clontech. n-Dodecyl-L-D-
maltoside (DDM) was from Calbiochem. The anti-rhodopsin mono-
clonal antibody 1D4, which speci¢cally recognizes the C-terminal
eight amino acids of rhodopsin (Glu-Thr-Ser-Gln-Val-Ala-Pro-Ala)
[10,11], was puri¢ed from hybridoma growth medium and coupled
to Sepharose 4B [12] for use in immunoa⁄nity puri¢cation of the
fusion proteins, as previously described for rhodopsin [13]. Peptide
I, with sequence Asp-Glu-Ala-Ser-Thr-Thr-Val-Ser-Lys-Thr-Glu-
Thr-Ser-Gln-Val-Ala-Pro-Ala corresponding to the C-terminal 18
amino acids of rhodopsin, was from American Peptide. 11-cis-Retinal
was synthesized according to published procedures [14].
2.2. Genes for fusion proteins rho/EGFP and rho/EGFPi
We prepared genes for two fusion proteins in this work using stan-
dard methods. Both genes were cloned between the EcoRI and NotI
cloning sites of the mammalian cell expression vector pMT3 [15].
Rho/EGFP (Fig. 1A) is composed of N-terminal rhodopsin followed
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by the entire coding sequence of EGFP followed by the C-terminal
eight codons of rhodopsin (epitope for the 1D4 antibody). Thus, there
are two copies of the C-terminal eight amino acids of rhodopsin in
this construct. This was necessary to ensure proper targeting of the
protein in rod photoreceptor cells [7] and to ensure that the fusion
protein would be recognized by the 1D4 antibody which requires a
C-terminal epitope [16].
Rho/EGFPi (Fig. 1B) is composed of full-length rhodopsin with the
coding sequence for EGFP inserted between amino acids Ala333 and
Ser334 in the C-terminal tail. Rho/EGFPi was designed to mimic the
Moritz et al. construct [1], and while not identical it does display a
similar phenotype with respect to in vitro assays for transducin acti-
vation and phosphorylation by RK, as is shown below.
2.3. Expression in COS cells and puri¢cation of the proteins
Rho/EGFP and rho/EGFPi were expressed transiently in COS cells
transfected using DEAE-dextran as described previously for rhodop-
sin [13]. Fluorescence microscopy employed an Olympus IX50/IX70
microscope equipped with a U-MWB (exciter ¢lter BP450^480 nm)
cube to follow expression of the fusion proteins in intact cells (photo-
graphs presented in Fig. 1C,D were taken 40 h post transfection).
Cells were harvested 72 h after initial exposure to DNA and treated
with 20 WM 11-cis-retinal in 10 mM sodium phosphate bu¡er, pH 7.0,
containing 150 mM NaCl (PBS) for 1 h to reconstitute the pigments
(all procedures beginning with and following initial treatment of the
sample with retinal were performed in the dark under illumination
from a 15 W incandescent bulb ¢ltered through a Kodak Safelight
#2 ¢lter). Cell membranes were solubilized in PBS containing 1%
(w/v) DDM and 0.1 mg/ml phenylmethylsulfonyl £uoride, and the
post-nuclear supernatant fraction applied to a 1D4-Sepharose 4B ma-
trix for puri¢cation of the fusion proteins by immunoa⁄nity chroma-
tography, as has been described previously for rhodopsin [13]. Bound
protein was eluted with 50 WM peptide I in PBS containing 0.1% (w/v)
DDM.
2.4. Absorption spectroscopy
UV/visible absorption spectra were obtained on a Hitachi model
U-3210 spectrophotometer modi¢ed by the manufacturer for dark
room use. All spectra were recorded on samples of 1.0 cm path length
and analyzed using Kaleidagraph (Version 3.08d). Fusion protein
spectra were analyzed by simulation using a linear combination of
constituent spectra recorded from puri¢ed samples of wild-type rho-
dopsin and EGFP after normalization on the basis of extinction co-
e⁄cient (O at 500 nm=42 700 cm31 M31 for rhodopsin [17] ; O at 488
nm=55 000 cm31 M31 for EGFP [Living Colors user manual, Clon-
tech]). The concentration of the protein for use in activity assays was
then determined from the rhodopsin component. An implicit assump-
tion in this analysis is that the spectral properties (absorption) of
rhodopsin and EGFP are una¡ected by being brought together in
the fusion protein. This assumption was judged to be reasonable on
the basis of the close ¢t of simulated to experimental spectra.
2.5. Miscellaneous procedures for in vitro characterization of the fusion
proteins
Western blot analysis [14] was performed using 2.8 pmol protein per
lane with 1D4 as the primary antibody and horseradish peroxidase-
conjugated anti-mouse IgG (Santa Cruz Biotechnology) as the sec-
ondary. Assays for the activation of transducin were performed
with 5 nM puri¢ed pigment by following the binding of [35S]guanosine
5P-O-(3-thiotriphosphate) as previously described [18]. Assays for
phosphorylation by RK were performed as described [19] using RK
from a post-nuclear supernatant fraction of transiently transfected
COS cells [20]. Reactions were carried out in mixtures containing
125 nM rhodopsin or fusion protein, 6 Wl RK extract, 75 mM [1,3-
bis[tris(hydroxymethyl)methylamino]propane] bu¡er, pH 6.7, 10 mM
Mg(OAc)2, 5 mM dithiothreitol, 0.01% DDM, and 100 WM
[Q-32P]ATP (2000 cpm/pmol). Reactions were performed either in
the dark or under light from a 300 W tungsten bulb ¢ltered through
a 490 nm cut-on ¢lter. Samples were incubated for 30 min at 30‡C and
then assayed by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis and autoradiography.
2.6. Transgenic X. laevis
Transgenic experiments were performed as previously described
[21]. Brie£y, transgenic X. laevis were generated by the method of
Kroll and Amaya using restriction enzyme-mediated integration of
DNA into sperm chromosomes prior to transplantation of the sperm
nuclei into unfertilized oocytes [3]. Cell-speci¢c expression in the pri-
mary rod photoreceptor cells of the Xenopus retina was achieved with
a vector (pXOP(3508/+41)Rho/EGFP) that is similar to those previ-
ously described [1,5,6] in which a fragment (nucleotides 3508 to +41)
from the X. laevis opsin promoter, XOP(3508/+41) [5,22], is used to
drive expression of rho/EGFP. The XOP promoter was isolated by
using polymerase chain reaction ampli¢cation of X. laevis genomic
DNA with the primers ATAAACTGCAGCCCCTAGGCCA and
CCAAAGGATCCCTAGAAGCCTG for the sense and antisense
strands, respectively, followed by digestion with PstI and BamHI to
obtain the 3508/+41 fragment [4].
2.7. Histochemistry and confocal microscopy
Histochemistry was performed essentially as previously described
[23]. Brie£y, transgenic tadpoles (1 month post injection, Vstage
51) were anesthetized in 0.25% (w/v) tricane solution, ¢xed with 4%
(w/v) paraformaldehyde in 0.1 M sodium phosphate bu¡er (PB), pH
7.2, at 4‡C overnight, incubated ¢rst with 5% and then 15% (w/v)
sucrose in PB at room temperature, and ¢nally embedded in TBS
(Triangle Biomedical Sciences) and frozen on dry ice. Cryosections
(16 Wm thickness) were prepared with a Jung CM3000 cryostat (Leica)
and then melt-mounted onto glass slides. Samples were allowed to
thaw in 0.1 M sodium phosphate bu¡er, pH 7.2, containing 150
mM NaCl (PBS*) at 37‡C. The tissue was then incubated in 5%
(v/v) goat serum (Sigma) in PBS* containing 0.3% (v/v) Triton
X-100 (PBS*-Tx) for 0.5 h. 1D4 antibody (1 Wg/ml diluted in PBS*-
Tx) was added and incubation continued for 3^4 h at room temper-
ature, the sample washed four times with PBS*-Tx, and incubated
with a 1:100 dilution of tetramethylrhodamine isothiocyanate-conju-
gated goat anti-mouse IgG (Sigma) for 1 h. The samples were covered
with 50% (v/v) glycerol in PB and coverslips and then used to obtain
images from a Leica TCS SP2 confocal scanning microscope (Leica
Microsystems). Fluorescence images were obtained using excitation
wavelengths of 488 nm for EGFP and 543 nm for rhodamine. The
Nomarski DIC images were obtained from a Zeiss Axioplan-2 optical
(Carl Zeiss) microscope equipped with Nomarski optic and GFP ¢lter
(FITC LP #41012, Chroma Technology).
3. Results and discussion
We prepared two di¡erent rho/EGFP fusion proteins (Fig.
1): one in which EGFP was inserted between amino acid
residues Ala333 and Ser334 in the C-terminal tail of rhodop-
sin (rho/EGFPi), and a second in which the coding sequence
for EGFP was placed after the last amino acid of full-length
rhodopsin and was itself followed by a repeat of the C-termi-
nal eight amino acids of rhodopsin (rho/EGFP). Rho/EGFPi
was designed to mimic the previously reported rho^GFP fu-
sion protein used to generate transgenic X. laevis [1]. Rho/
EGFP was designed with hope of improving the functional
characteristics of the fusion protein by moving the EGFP
domain further from potentially important amino acid resi-
dues near the cytoplasmic surface of rhodopsin. As is shown
in Fig. 1C,D, both proteins were expressed on the membrane
surface of COS cells as judged by the characteristic pattern of
di¡use green £uorescence covering the entire cell outline.
UV/visible absorption spectra for reconstituted and puri¢ed
rho/EGFP and rho/EGFPi are shown in Fig. 2A,B. Both pro-
teins display an absorption maximum at about 488 nm with
long-wavelength shoulder above 530 nm, indicating the pres-
ence of chromophores from rhodopsin and EGFP. Both spec-
tra are reasonably well simulated by a linear combination of
spectra for the isolated wild-type rhodopsin and EGFP. Rho/
EGFP is ¢t well by a combination of 1 rhodopsin plus 0.9
EGFP, indicating that both domains are folded properly in a
majority of the molecules. In contrast, the spectrum of rho/
EGFPi is ¢t with a combination of 1 rhodopsin and 0.5
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EGFP. This ratio suggests that the EGFP domain is unable to
adopt a native conformation in at least 50% of the molecules.
In addition, rho/EGFP expresses to higher levels in COS cells
(80% that of wild-type rhodopsin) than does rho/EGFPi (38%
that of wild-type rhodopsin), as judged by the yield of rho-
dopsin pigment (not shown).
Western blot analysis of rho/EGFP and rho/EGFPi is dis-
played in Fig. 3A. The fusion proteins separate into two
bands, as has been described before for rho^GFP [1], with
relative intensity a variable of di¡erent preparations. The elec-
trophoretic mobilities are less than that of wild-type rhodop-
sin, as is expected from their larger molecular weight. We do
Fig. 1. Schematic representation of rhodopsin/EGFP fusion proteins rho/EGFP (A) and rho/EGFPi (B), and £uorescence images of COS cells
expressing rho/EGFP (C) or rho/EGFPi (D). Shaded circles in A and B indicate location of the 1D4 epitope. Although there are two 1D4 epi-
topes in rho/EGFP (A), only the one at the C-terminus of the protein is expected to be recognized by the 1D4 antibody (see Section 2). Scale
bar in C and D=40 Wm.
Fig. 2. Absorption spectra of puri¢ed rho/EGFP (A) and rho/EGFPi (B). In each case: black, experimental spectrum for the puri¢ed fusion
protein; cyan, simulated spectrum generated by a linear combination of spectra for wild-type rhodopsin (red) and EGFP (green). A: Simulated
spectrum generated from 1 rhodopsin and 0.9 EGFP. B: Simulated spectrum generated from 1 rhodopsin and 0.5 EGFP. Simulated and exper-
imental spectra deviate somewhat at shorter wavelengths (less than 430 nm) due to increasing contribution of light scattering in the fusion pro-
tein samples that is not present in the wild-type rhodopsin and EGFP template spectra. This is more of a problem for the rho/EGFPi sample
because of lower absorbance resulting from decreased expression level and ability to fold properly.
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not have a good explanation at this time for why the mobil-
ities of fast bands of the two fusion proteins appear to be so
di¡erent. The fact that the overall intensities of rhodopsin,
rho/EGFP, and rho/EGFPi are similar suggests that the prep-
arations do not contain substantial amounts of unfolded op-
sin (since the amount of protein in each lane was based on the
amount of 11-cis-retinal chromophore).
Rho/EGFP and rho/EGFPi both activate transducin in a
light-dependent manner, as is shown in Fig. 3B. However,
rho/EGFPi has a much reduced speci¢c activity in comparison
to both wild-type rhodopsin and rho/EGFP, as is also the case
for rho^GFP [1]. The speci¢c activities of wild-type rhodopsin
 
Fig. 4. Confocal and Nomarski images of a retina from a 1-month-
old transgenic tadpole expressing rho/EGFP. Confocal images were
obtained with transmitted light (A), or £uorescence following excita-
tion at 488 nm (B, intrinsic £uorescence from the EGFP-tagged rho-
dopsin) or 543 nm (C, immunocytochemical £uorescence with 1D4
antibody). D: Superposition with blue background of images in A^
C. E: Superposition of transmitted and £uorescence (GFP ¢lter)
light Nomarski DIC images taken from the same tissue as in A^D.
Retina layers as indicated in A are: retinal pigmented epithelium
(RPE), and photoreceptor cell outer (OS) and inner segments (IS).
Scale bar, 15 Wm.
Fig. 3. In vitro characterization of the fusion proteins. A: Western
blot analysis of the proteins puri¢ed from transfected COS cells.
The stacking gel was removed, and only the running gel was trans-
ferred to nitrocellulose. Each lane contains 2.8 pmol pigment. Ar-
rows indicate location of more rapidly migrating band. B: Transdu-
cin activity assays. Conditions were as described in Section 2.
Circles, wild-type rhodopsin; triangles, rho/EGFP; squares, rho/
EGFPi ; solid symbols, reaction in the dark; open symbols, reaction
after exposure to light (he). C: RK assays. Conditions were as de-
scribed in Section 2. Substrates for RK were wild-type rhodopsin
(rho), rho/EGFP, or rho/EGFPi, as indicated in the ¢gure. Lanes 1,
3, and 5, reaction in the dark; lanes 2, 4, 6, reaction after exposure
to light for 30 min. Arrows: a, autophosphorylated RK; b, phos-
phorylated rho/EGFP; c, phosphorylated wild-type rhodopsin.
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and rho/EGFP (both 101.6 pmol/min/pmol) are three times
that of rho/EGFPi (33.4 pmol/min/pmol). An even greater
di¡erence is observed in RK assays. As is shown in Fig. 3C,
RK phosphorylates wild-type rhodopsin and rho/EGFP in
light-dependent reactions with roughly the same amount of
phosphate incorporated in the two proteins after a 30-min
incubation period. In stark contrast, rho/EGFPi shows little
if any incorporation of phosphate under the same conditions,
as has been noted earlier by Moritz et al. for rho^GFP [1].
It is clear that the design of rho/EGFP represents an im-
provement over rho/EGFPi and rho^GFP [1] in terms of in
vitro activity assays, but what about cellular location of the
protein in rod photoreceptor cells? As is shown in Fig. 4, rho/
EGFP does not disrupt proper targeting of rhodopsin to the
outer segment of rod photoreceptor cells in the Xenopus ret-
ina. Rho/EGFP displays the same mosaic expression pattern
and outer segment location as observed for rho^GFP by Mor-
itz et al. [1]. Thus, movement of the EGFP domain to the C-
terminus of rhodopsin (and followed by a repeat of the 1D4
epitope as indicated in Fig. 1) does not appear to adversely
a¡ect expression or tra⁄cking of the protein in the rod photo-
receptor cells of transgenic animals.
In summary, the placement of the EGFP domain in rho/
EGFP results in a signi¢cant improvement in the ability of the
fusion protein to activate transducin and serve as a substrate
for RK, and maintains the signals responsible for proper tar-
geting of the protein to outer segments of rod photoreceptor
cells. As a consequence, rho/EGFP is a more appropriate
choice for studies in which phototransduction is the focus of
transgenesis experiments.
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